Wu Guifu, Du Zhimin, Hu Chenghen, Zheng Zhensheng, Zhan Chengyang, Ma Hong, Fang Dianqiu, Ahmed Khan Tanveer, Laham Roger J, Hui John C K, Lawson William E
Cardiology and the Key Lab on Assisted Circulation of the Health Ministry of China, The First Affiliated Hospital/Sun Yat-sen University, Guangzhou, People's Republic of China.
Am J Physiol Heart Circ Physiol. 2006 Jan;290(1):H248-54. doi: 10.1152/ajpheart.01225.2004. Epub 2005 Aug 19.
Enhanced external counterpulsation (EECP) is an effective noninvasive treatment of coronary artery disease. Its mechanism of action remains unknown. An acute coronary occlusion dog model was created to explore the angiogenic effect of EECP. After coronary occlusion, 12 dogs were randomly assigned to either EECP (n = 6) or control (n = 6). Immunohistochemical studies of alpha-actin and von Willebrand factor (vWF) were used to detect newly developed microvessels. Systemic and local vascular endothelial growth factor (VEGF) were identified by ELISA and reverse transcriptase PCR analysis. There was a significant increase in the density of microvessels per squared millimeter in the infarcted regions of the EECP group compared with the control group (vWF, 15.2 +/- 6.3 vs. 4.9 +/- 2.1, P < 0.05; alpha-actin, 11.8 +/- 5.3 vs. 3.4 +/- 1.2, P < 0.05). The positive-stained area per squared micrometer also increased significantly (alpha-actin, 6.6 x 10(3) +/- 2.9 x 10(3) microm2 vs. 0.6 x 10(3) +/- 0.5 x 10(3) microm2, P < 0.05; vWF, 5.7 x 10(3) +/- 1.9 x 10(3) microm2 vs. 1.7 x 10(3) +/- 1.4 x 10(3) microm2, P < 0.05). Immunohistochemical staining and reverse transcriptase PCR analysis documented a significant increase in VEGF expression. These factors associated with angiogenesis corresponded to improved myocardial perfusion by 99mTc-sestamibi single-photon emission computed tomography. Angiogenesis may be a mechanism of action for the improved myocardial perfusion demonstrated after EECP therapy.
增强型体外反搏(EECP)是一种治疗冠状动脉疾病的有效非侵入性疗法。其作用机制尚不清楚。建立急性冠状动脉闭塞犬模型以探讨EECP的血管生成作用。冠状动脉闭塞后,12只犬被随机分为EECP组(n = 6)或对照组(n = 6)。采用α-肌动蛋白和血管性血友病因子(vWF)免疫组化研究检测新生成的微血管。通过酶联免疫吸附测定(ELISA)和逆转录聚合酶链反应(PCR)分析鉴定全身和局部血管内皮生长因子(VEGF)。与对照组相比,EECP组梗死区域每平方毫米微血管密度显著增加(vWF:15.2±6.3对4.9±2.1,P<0.05;α-肌动蛋白:11.8±5.3对3.4±1.2,P<0.05)。每平方微米阳性染色面积也显著增加(α-肌动蛋白:6.6×10³±2.9×10³μm²对0.6×10³±0.5×10³μm²,P<0.05;vWF:5.7×10³±1.9×10³μm²对1.7×10³±1.4×10³μm²,P<0.05)。免疫组化染色和逆转录PCR分析表明VEGF表达显著增加。这些与血管生成相关的因素与通过99mTc-甲氧基异丁基异腈单光子发射计算机断层扫描改善的心肌灌注相对应。血管生成可能是EECP治疗后心肌灌注改善的一种作用机制。